Vivos Closes No-Cash SOD Deal, Claims $10M+ Equity Boost and Nasdaq Cure
VVOS sits 27% above its 52-week low of $0.125 on light trading volume (0.4× avg).
Summary
Vivos closed the SOD Sciences transaction it announced in the October 15 8-K, issuing 12,000 Series C convertible preferred shares with a $12 million stated value for an 11% SOD stake and 50% of its pseudohypoxia test. No cash changed hands. Management expects the preferred to sit in permanent equity, adding more than $10 million to stockholders' equity and pushing the company back above Nasdaq's $2.5 million minimum — a critical fix given the going concern warning and $1.8 million cash balance in the Q2 10-Q. The conversion price of $0.15 is a premium to the price when the agreement was signed, but conversion could eventually mean up to 80 million new shares, capped at 19.99% until shareholders approve. The 325,000-patient AHA channel is the real story, though it is entirely contingent on definitive agreements and AHA's bankruptcy court approval, with revenue not expected before 2027. The preliminary proxy filed today seeks approval of a 1-for-20 to 1-for-40 reverse split to cure the bid-price deficiency, so dilution and listing mechanics remain the near-term overhang.
At the time of this announcement, VVOS was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.12 to $3.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.